Tags : Repatha

Biotech

Amgen Reports In-Favor Uphold of its Two Patents for Repatha

Shots: Amgen receives in-favor upholding validity for Repatha from Delaware Jury, with two out of five asserted claims based on its patents meeting the legal requirements of written description and enablement In Mar,2016 Sanofi and Regeneron admitted infringement of Amgen’s patents, regaining Amgen with two patents of Repatha but was overturned on appeal in the […]Read More

Biotech

Amgen Reports Safety & Efficacy Results of Repatha (evolocumab) in

Shots: The OSLER-1 (Open-Label Study of Long-TERm Evaluation Against LDL-C) study involves assessing of Repatha (420 mg) + SoC or SoC alone in patients with hypercholesterolemia in ratio (2:1) across 192 sites in 18 countries OSLER-1 (N≤ 1324) study results: reduction in mean LDL-C @1/2/3/4/5yrs. (59%, 56%, 57%, 56%, 56%). Another study GOULD is practiced in patients […]Read More